Who
Michael R. McMullen
Director
Company insider
Files Form 4 as: Director, Bristol-Myers Squibb; Director, Kla; CEO and President, Agilent Technologies; Director, Coherent.
In numbers
- Trades disclosed
- 277
- Buys
- 0
- Sells
- 58
- Bought
- $0
- Sold
- $140.4M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 19 Nov 2007
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K560.897 at $62.40 | filing |
| 30 Jun 2026filed 2 Jul 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K607.428 at $57.62 | filing |
| 30 Jun 2026filed 2 Jul 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K607.43 at $57.62 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K577.082 at $60.65 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K577.08 at $60.65 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K3,996.367 at $55.05 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K3,996.37 at $55.05 | filing |
| 31 Dec 2025filed 5 Jan 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —648.869 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —648.87 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | KLAC KlaSemiconductor Equipment | SEC FORM 4 Code A | —203.73 at $0.00 | filing |
| 30 Sep 2025filed 2 Oct 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —776.05 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —728.36 at $0.00 | filing |
| 31 Mar 2025filed 1 Apr 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $31K512.38 at $60.99 | filing |
| 1 Feb 2025filed 4 Feb 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $210K3,562.34 at $58.95 | filing |
| 31 Dec 2024filed 2 Jan 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $31K552.51 at $56.56 | filing |
| 6 Nov 2024filed 8 Nov 2024 | KLAC KlaSemiconductor Equipment | SEC FORM 4 Code A | —350 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $31K603.98 at $51.74 | filing |
| 29 Jul 2024filed 31 Jul 2024 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code J | —5 at $0.00 | filing |
| 1 Jul 2024filed 2 Jul 2024 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $123K2,986.94 at $41.30 | filing |
| 8 Mar 2024filed 12 Mar 2024 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $7.8M52,297 at $150.00 | filing |
News
Agilent Technologies, Inc. $A Stock: Stone Summit Wealth LLC Lowers HoldingsA · dailypolitical.com · 14 Oct 2026Agilent Technologies: Agilent to buy pathology software maker Proscia for $240 millionA · indiatimes.com · 13 Oct 2026
0 headlines in the last 90 days name Michael R. McMullen; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.